Zevra Therapeutics (NASDAQ:ZVRA) Research Coverage Started at Guggenheim

Guggenheim assumed coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research report report published on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $20.00 price target on the stock.

Several other equities analysts have also issued reports on the company. Maxim Group boosted their price target on Zevra Therapeutics from $18.00 to $25.00 and gave the company a buy rating in a research note on Tuesday, September 24th. Canaccord Genuity Group cut their target price on Zevra Therapeutics from $24.00 to $22.00 and set a buy rating for the company in a research note on Wednesday, September 18th. HC Wainwright reiterated a buy rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Monday, September 30th. JMP Securities began coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an outperform rating and a $17.00 price objective for the company. Finally, Roth Mkm lifted their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a buy rating in a research report on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Zevra Therapeutics currently has an average rating of Buy and a consensus price target of $20.83.

Zevra Therapeutics Stock Performance

ZVRA stock opened at $7.92 on Monday. The firm has a 50 day simple moving average of $7.41 and a 200 day simple moving average of $5.86. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $8.95. The stock has a market cap of $331.48 million, a P/E ratio of -5.87 and a beta of 1.94. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. The company had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. During the same period last year, the business earned ($0.15) EPS. Research analysts anticipate that Zevra Therapeutics will post -1.59 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Thomas Anderson acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, July 16th. The shares were purchased at an average cost of $6.81 per share, with a total value of $68,100.00. Following the completion of the purchase, the director now owns 20,000 shares of the company’s stock, valued at $136,200. This represents a 100.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Several institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD bought a new position in shares of Zevra Therapeutics in the first quarter worth about $64,000. The Manufacturers Life Insurance Company increased its holdings in shares of Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after purchasing an additional 2,452 shares in the last quarter. SG Americas Securities LLC bought a new position in Zevra Therapeutics in the 3rd quarter worth approximately $105,000. City State Bank lifted its holdings in Zevra Therapeutics by 14.1% during the 3rd quarter. City State Bank now owns 16,224 shares of the company’s stock worth $113,000 after buying an additional 2,000 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Zevra Therapeutics during the 4th quarter worth $177,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.